Last reviewed · How we verify
Edoxaban plus Single Antiplatelet Agent
Edoxaban inhibits Factor Xa to prevent blood clot formation, while a single antiplatelet agent (such as aspirin or clopidogrel) blocks platelet aggregation, providing dual antithrombotic protection.
Edoxaban inhibits Factor Xa to prevent blood clot formation, while a single antiplatelet agent (such as aspirin or clopidogrel) blocks platelet aggregation, providing dual antithrombotic protection. Used for Acute coronary syndrome (with single antiplatelet agent), Stroke prevention in atrial fibrillation (with single antiplatelet agent in select patients).
At a glance
| Generic name | Edoxaban plus Single Antiplatelet Agent |
|---|---|
| Sponsor | Gi-Byoung Nam |
| Drug class | Factor Xa inhibitor + antiplatelet agent combination |
| Target | Factor Xa (edoxaban component); P2Y12 or COX-1 (antiplatelet component, depending on agent) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Edoxaban is a direct Factor Xa inhibitor that disrupts the coagulation cascade by preventing thrombin generation. When combined with a single antiplatelet agent, this dual therapy targets both the coagulation and platelet pathways, reducing thrombotic risk in patients requiring combined anticoagulation and antiplatelet therapy. This combination is used in acute coronary syndrome or other conditions where both pathways require inhibition.
Approved indications
- Acute coronary syndrome (with single antiplatelet agent)
- Stroke prevention in atrial fibrillation (with single antiplatelet agent in select patients)
Common side effects
- Bleeding (major and minor)
- Gastrointestinal bleeding
- Intracranial hemorrhage
- Dyspepsia
Key clinical trials
- Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial (PHASE3)
- Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress (PHASE4)
- Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis (PHASE4)
- Edoxaban Versus Edoxaban With antiPlatelet Agent In Patients With Atrial Fibrillation and Chronic Stable Coronary Artery Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Edoxaban plus Single Antiplatelet Agent CI brief — competitive landscape report
- Edoxaban plus Single Antiplatelet Agent updates RSS · CI watch RSS
- Gi-Byoung Nam portfolio CI